This page is updated frequently with new Immune Disease-related patent applications.
|Predictive biomarkers for detection of organ damage in autoimmune illnesses and other diseases|
The invention provides methods for identifying the presence of, or an increased risk of developing, organ damage in a subject having an autoimmune disease, for example, systemic lupus erythematosus (sle) or mixed connective tissue disease (mctd), or other disease in which the lungs and/or kidneys are involved. In one embodiment, a significantly increased combined igm reactivity against the peptides having the sequences of seq id nos: 4, 9, 12, and 15 in a sample obtained from a patient compared to a healthy control indicates lung damage or an increased risk of developing lung damage in the subject.
The Florida International University Board Of Trustees
|Use of glycan as biomarkers for autoimmune diseases|
The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed..
Macau University Of Science And Technology
|Stimulation via tlr4/md-2 to reverse type 1 diabetes|
Disclosed are methods and compositions for treating type i diabetes in a subject. Agents selected from a tlr4 agonist, a tlr4/md-2 agonist, or a combination thereof may be used in the disclosed methods and compositions.
University Of Cincinnati
This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Ma Inc.
|Nkt cell ligands and methods of use|
Alpha-glycosylceramide compounds capable of activating nkt cells and compositions thereof are disclosed. Methods for activating nkt cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed..
Brigham Young Unversity
|Heterocyclic compounds and uses thereof|
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, egfr (including her), alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, btk, or jak, and the respective pathways.. .
Acea Biosciences Inc.
The present invention relates to compounds according to general formula (i); to compositions, including a pharmaceutical formulation and a combination preparation comprising one or more of the compound (s); to a process for their preparation; to uses thereof, including the use in the treatment or prevention of a viral infection or a th17-associated inflammatory and/or autoimmune disease.. .
Twincore Zentrum Für Klinische Infektionsforschung Gmbh
|Mmf-derivatives of ethyleneglycols|
The present invention relates to novel compounds, e.g. For use as a medicament.
|Treatment of autoimmune disorders and infections using antagonists of sgk1 activity|
The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
The Johns Hopkins University
|Sip modulator immediate release dosage regimen|
The present invention relates to siponimod (baf312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.. .
Autoimmunity and multiple sclerosis treatment
A method for alleviating a symptom of multiple sclerosis or other autoimmune or inflammatory disease includes a step of identifying a subject having multiple sclerosis or other autoimmune diseases. A fasting mimicking diet is administered to the subject for a first predetermined time period, the fasting mimicking diet providing less than 50% of the subject's normal caloric intake.
University Of Southern California
Surrogates of post-translationally modified proteins and uses thereof
The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
President And Fellows Of Harvard College
Methods of treating inflammatory and autoimmune diseases with natalizumab
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
T-cell redirecting bispecific antibodies for treatment of disease
The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.
Combination therapy for the treatment of autoimmune diseases
The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of t-cells that are used in combination with antagonists of the cytokine cxcl10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v.
Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..
Immune Disease topics:
Type 1 Diabetes
Signs And Symptoms
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.